RNA Immunoprecipitation (RIP) Protocol: RBP-RNA Enrichment and Analysis

RNA immunoprecipitation (RIP) is an antibody-based method used to isolate an RNA-binding protein (RBP) together with RNA molecules associated with that protein. The immunoprecipitated RNA can then be analysed by RT-qPCR, microarray or RNA sequencing to determine which transcripts are enriched with the RBP.

RIP is conceptually similar to immunoprecipitation and ChIP, but RNA introduces additional experimental constraints: RNases must be controlled throughout the workflow, RNA abundance can change rapidly, and a recovered RNA may be associated with the immunoprecipitated protein either directly or through a larger ribonucleoprotein complex.

Use this SOP as a starting framework. Native RIP and cross-linked RIP answer related but not identical questions. Antibody quality, RNase control, lysis chemistry, wash stringency and the choice of input/negative RNA controls strongly influence the result.

What does RIP measure?

RIP measures enrichment of RNA molecules associated with a chosen RNA-binding protein under the lysis and immunoprecipitation conditions used. A positive RIP result does not automatically establish a direct protein–RNA contact. The RNA can be bound directly by the RBP, associated through another protein, or retained within a larger ribonucleoprotein complex.

For high-confidence mechanistic claims, RIP is often combined with additional approaches such as mutational analysis, purified-protein binding assays, CLIP-derived methods, reporter assays or perturbation of the RNA-binding protein.

Native RIP versus cross-linked RIP

When to use RIP

• Test whether an RBP associates with a candidate mRNA or non-coding RNA.
• Compare RNA association before and after stimulation, drug treatment or genetic perturbation.
• Validate candidate interactions identified by transcriptomic or computational analysis.
• Measure enrichment of a defined RNA by RIP-qPCR.
• Profile a larger set of associated RNAs by RIP-seq.
• Compare wild-type and RNA-binding-defective RBP mutants.

Equipment required

• RNase-controlled work area.
• Refrigerated microcentrifuge.
• End-over-end rotator suitable for 4°C.
• Magnetic rack for magnetic Protein A/G beads or suitable centrifuge for agarose beads.
• RNase-free tubes and filter tips.
• RNA purification system compatible with small RNA quantities.
• Reverse-transcription and qPCR equipment for targeted analysis.
• Optional sequencing library-preparation workflow for RIP-seq.

Reagents

• Cells or tissue expressing the RNA-binding protein of interest.
• RNase-free PBS.
• RNase-free lysis buffer compatible with preservation of RNP complexes.
• RNase inhibitor.
• Protease inhibitor cocktail.
• Target-specific antibody suitable for immunoprecipitation.
• Species- and isotype-matched control IgG.
• Protein A/G beads compatible with the antibody.
• RNase-free wash buffer.
• Proteinase K where used.
• RNA purification reagents.
• Reverse-transcription and qPCR reagents or sequencing reagents.

RNase-free preparation

RNA degradation is one of the most common reasons for weak or irreproducible RIP results. Use clean gloves, RNase-free consumables and freshly prepared or certified RNase-free buffers. Keep samples cold unless the protocol specifies otherwise, and add RNase inhibitor to lysis and wash buffers at the stage recommended for the chosen method.

• Use dedicated RNase-free pipettes where possible.
• Clean work surfaces and equipment before starting.
• Avoid repeated freeze–thaw cycles of RNA-containing samples.
• Keep a small input aliquot for RNA-integrity and expression checks.

Experimental design before starting

Choose a suitable antibody

RIP depends on immunoprecipitation performance. Prefer an antibody with evidence for IP/RIP use or demonstrate that it can efficiently recover the RBP under native conditions. An antibody that works in western blot may recognise a denatured epitope that is inaccessible in native RIP.

Plan RNA controls

Choose at least one candidate target RNA and one negative-control RNA that should not associate with the RBP. For qPCR, validate primer specificity and efficiency before analysing immunoprecipitated material.

Reserve input

Input RNA is required to determine whether differences in RIP enrichment are simply caused by different starting transcript abundance.

Detailed native RIP protocol

1. Harvest cells. Collect the experimental sample using RNase-free reagents and minimise handling time.
2. Wash with cold RNase-free PBS. Remove residual culture medium while keeping the sample cold.
3. Lyse cells. Add ice-cold RIP lysis buffer containing RNase and protease inhibitors. Use a buffer mild enough to preserve the RNP complex while efficiently releasing the RBP.
4. Clarify lysate. Centrifuge at 4°C to remove insoluble material. Transfer the supernatant to a clean RNase-free tube.
5. Reserve input. Remove a defined fraction of lysate before immunoprecipitation. This input should be processed alongside the RIP material later.
6. Optional pre-clear. Incubate lysate with unloaded beads to reduce matrix-binding background. Use consistently across conditions if included.
7. Prepare antibody-bead complexes. Incubate the target-specific antibody with Protein A/G beads or add antibody to lysate before bead capture, depending on the chosen workflow.
8. Set up controls. Prepare matched IgG and, where useful, beads-only control reactions using equivalent lysate input.
9. Incubate lysate with antibody/beads. Rotate at 4°C. Several hours or overnight can be used depending on antibody affinity and target abundance; optimise for signal-to-background rather than assuming longer is always better.
10. Collect beads. Use a magnetic rack or gentle centrifugation appropriate to the bead chemistry.
11. Wash immunoprecipitates. Perform multiple washes with cold RNase-free wash buffer. Increase wash stringency only if non-specific RNA/background is excessive.
12. Remove residual wash buffer. Avoid drying the beads excessively.
13. Digest protein. Release associated RNA by treating the bead complexes with Proteinase K or another validated method.
14. Purify RNA. Use a column or phenol/chloroform-based method suited to low RNA amounts. Include carrier or low-input workflow only if it is compatible with downstream quantification.
15. Assess RNA quality and quantity where feasible. RIP RNA can be below the reliable range of conventional spectrophotometry, so avoid over-interpreting low-concentration purity ratios.
16. Reverse transcribe. Convert input and immunoprecipitated RNA to cDNA using the same reverse-transcription conditions.
17. Analyse enrichment. Quantify target and negative-control transcripts by qPCR, or proceed to sequencing/library preparation.

Cross-linked RIP considerations

Chemical cross-linking can stabilise RNA-protein and protein-protein associations before lysis. Formaldehyde-cross-linked RIP has been used successfully for RIP-qPCR and RIP-seq, but it can also preserve indirect, protein-bridged associations and may reduce antibody accessibility. Cross-linking concentration and time therefore need to be validated for the specific RBP, cell type and downstream readout.

Do not treat UV 254 nm cross-linking as the default RIP method. UV cross-linking is characteristic of CLIP-family workflows designed to enrich direct protein-RNA contacts. If a RIP experiment uses cross-linking, the chemistry and reversal conditions should be specified explicitly and interpreted in the context of that method.

Controls that make RIP interpretable

• Input RNA: measures transcript abundance before immunoprecipitation.
• IgG control: identifies RNA recovered non-specifically through antibody/bead background.
• Beads-only control: identifies RNA binding directly to the support.
• Known target RNA: useful as a positive control when the RBP's biology is established.
• Negative-control RNA: a transcript not expected to interact with the RBP.
• RBP knockout/knockdown: a strong biological specificity control where available.
• RNA-binding-defective RBP mutant: useful for mechanistic validation.

RIP-qPCR primer validation

• Design amplicons that are short enough for the expected RNA-fragment distribution.
• Confirm a single product and include a no-template control.
• Use a dilution series to check linearity; published RIP-qPCR workflows recommend demonstrating acceptable amplification efficiency rather than assuming the primer pair is quantitative.
• Include a negative RNA region or transcript that is detectable in input but not expected to associate with the RBP.
• Include a no-reverse-transcriptase control where genomic DNA could contribute to signal.

RIP-qPCR analysis

There are several valid ways to report RIP-qPCR data. The chosen method should be defined before analysis and applied consistently.

Percent input

Calculate the proportion of input RNA recovered in the immunoprecipitate after correcting for the fraction of input reserved. This is useful when comparing enrichment of different RNAs in the same experiment.

Fold enrichment over IgG

Compare target RNA abundance in the specific IP with the matched IgG control. This is intuitive but can become unstable when IgG signal is close to the qPCR detection limit.

Relative target versus negative RNA

Comparing a candidate target RNA with a negative-control transcript can demonstrate selectivity, especially when both are present at measurable abundance in input.

RIP-seq considerations

• Use biological replicates rather than one pooled experiment.
• Process input and control IP libraries in parallel.
• Use low-input library methods compatible with the RNA amount recovered.
• Control for transcript abundance: abundant RNAs can appear enriched simply because they are abundant in input.
• Confirm sequencing hits by independent RIP-qPCR or another orthogonal method.

Native RIP versus CLIP

RIP identifies RNA associated with an immunoprecipitated protein complex. CLIP-derived methods use covalent cross-linking and sequencing strategies designed to map direct binding sites at higher resolution. RIP is simpler and often suitable for targeted enrichment studies, while CLIP methods are preferable when nucleotide-level binding-site information is required.

Warnings and common mistakes

• Do not interpret RIP enrichment as proof of direct binding. Native RNP complexes can contain multiple proteins.
• Do not ignore transcript abundance. Compare enrichment with input.
• Do not use an antibody solely because it works in western blot. Native IP performance matters.
• Do not work without an IgG control. Beads and antibodies can recover RNA non-specifically.
• Do not assume more stringent washing is always better. Weak but genuine RNP interactions can be lost.
• Do not treat low-input RNA purity ratios from a spectrophotometer as reliable QC on their own.

Limitations

• Native RIP can lose transient or weak interactions during lysis and washing.
• Cross-linking can stabilise indirect associations and complicate interpretation.
• RNA degradation can produce false-negative results.
• Antibody specificity and IP efficiency are major determinants of assay quality.
• Highly abundant RNAs can dominate sequencing libraries.
• RIP does not inherently identify the exact RNA-binding site.

Troubleshooting

Frequently asked questions

Does RIP prove direct protein–RNA binding?

Not necessarily. Native RIP can recover RNA through multiprotein complexes. Direct binding requires a more defined biochemical or cross-linking-based validation strategy.

Should I use native or cross-linked RIP?

Native RIP preserves complexes without cross-link-induced artefacts but can lose weak interactions. Cross-linked RIP stabilises interactions but can complicate interpretation. Choose based on the biological question.

Can I use any IP antibody for RIP?

An IP-compatible antibody is a strong starting point, but it should still be tested in the actual RIP buffer and sample because RNase-free conditions and RNP complexes can alter recovery.

How much input should I reserve?

Reserve a defined and documented fraction sufficient for RNA extraction and downstream qPCR or sequencing. Use the same fraction across samples so percent-input calculations are comparable.

References and primary methods

1. Protocol for evaluating RNA-protein associations in mammalian cells with RIP-seq and RIP-qPCR. STAR Protocols. 2025. PMID: 41455104.
2. Studying RNA-binding protein interactions with target mRNAs in eukaryotic cells: native ribonucleoprotein immunoprecipitation assays. Methods Mol Biol.
3. Method for isolation and identification of RNAs and protein components of ribonucleoprotein complexes using RIP-Chip. J Vis Exp. 2012.
4. RNA immunoprecipitation to identify in vivo targets of RNA editing and modifying enzymes. Methods Mol Biol. 2021.
5. RNA-binding protein immunoprecipitation to examine AUF1 binding to senescence-associated mRNAs. Bio-protocol. 2016.

Relevant ABMIUM products

RIP requires an antibody capable of immunoprecipitating the RBP under the chosen conditions. ABM1317 Anti-Human/Mouse/Rat AGO2 Antibody [B542] is explicitly listed in the ABMIUM catalogue for IP as well as WB, IHC, IF/ICC and ELISA, making it a rational candidate for AGO2-centred RIP assay development. It should not be described as RIP-validated until RNA co-enrichment is demonstrated in the relevant system.

For orthogonal or biochemical work, ABM16285 Recombinant Human AGO2 (His Tag) and ABM14386 Recombinant Human hnRNPK (GST, His Tag) are also available. For another RBP, use Find your MATCH and we can compare IP evidence, species reactivity and the planned RIP-qPCR/RIP-seq workflow before selection.

Related ABMIUM protocols

• Immunoprecipitation (IP) Protocol
• Co-Immunoprecipitation (Co-IP) Protocol
• PCR, RT-PCR and qPCR Protocol
• Pull-Down Assay Protocol

Explore more with ABMIUM

For a different RNA-binding protein, use Find your MATCH with the RBP, species and downstream analysis, or explore IP-compatible antibodies. Related workflows: IP, Co-IP and RT-qPCR.